Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 9-10, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koenig, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koenig, W.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:9-10.)
© 2001 American Association for Clinical Chemistry, Inc.

Editorial

C-Reactive Protein and Cardiovascular Risk: Has the Time Come for Screening the General Population?

Wolfgang Koenig

Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Robert-Koch Strasse 8, D-89081 Ulm, Germany, Fax 49-731-503-3872, wolfgang.koenig@medizin.uni-ulm.de

C-Reactive protein (CRP), an exquisitely sensitive marker of systemic inflammation, has emerged as a powerful predictor of cardiovascular diseases, in particular of coronary heart disease (CHD) (1). The availability of high-sensitivity (hs) assays has enabled the detection of even low-grade inflammatory responses that have previously been regarded as clinically not meaningful.

In this issue of the Journal, Rifai and Ridker (2) propose an algorithm using CRP concentrations together with the total cholesterol:HDL-cholesterol ratio, the most powerful predictor among lipoproteins, for cardiovascular risk assessment. They suggest risk stratification based on two consecutive hs-CRP measurements and categorizing subjects according to quintiles of hs-CRP and total cholesterol:HDL-cholesterol ratio. These quintiles were derived from ongoing population-based surveys, whereas risk estimates were taken from prospective studies in men and in women.

CRP fulfills most of the requirements needed to serve as a new risk factor for CHD: (a) The consistency of results from 11 prospective population-based studies in initially healthy subjects has been remarkable. (b) The association between CRP and future coronary events is strong. The combined risk ratio for CHD from metaanalysis is 2 if subjects with baseline CRP concentrations in the upper tertile of the population distribution are compared with those in the lower . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. S. Levinson, J. J. Miller, and R. J. Elin
Poor Predictive Value of High-Sensitivity C-Reactive Protein Indicates Need for Reassessment
Clin. Chem., October 1, 2004; 50(10): 1733 - 1735.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
U. A. Ajani, E. S. Ford, and A. H. Mokdad
Prevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values
Clin. Chem., September 1, 2004; 50(9): 1618 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Imhof, M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, G. D.O. Lowe, and W. Koenig
Distributions of C-reactive Protein Measured by High-Sensitivity Assays in Apparently Healthy Men and Women from Different Populations in Europe
Clin. Chem., April 1, 2003; 49(4): 669 - 672.
[Full Text] [PDF]

Home page
 CirculationHome page
T. A. Pearson, G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon III, M. Criqui, Y. Y. Fadl, S. P. Fortmann, Y. Hong, G. L. Myers, et al.
Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Circulation, January 28, 2003; 107(3): 499 - 511.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Ishibashi, Y. Takemura, H. Ishida, K. Watanabe, and T. Kawai
C-Reactive Protein Kinetics in Newborns: Application of a High-Sensitivity Analytic Method in Its Determination
Clin. Chem., July 1, 2002; 48(7): 1103 - 1106.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
R.J. de Winter, G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, et al.
The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty
Eur. Heart J., June 2, 2002; 23(12): 960 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
I. Kushner and A. R. Sehgal
Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?
Arch Intern Med, April 22, 2002; 162(8): 867 - 869.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.